U.S. FDA approves Novartis biosimilar to Amgen's Enbrel

Reuters Health Information: U.S. FDA approves Novartis biosimilar to Amgen's Enbrel

U.S. FDA approves Novartis biosimilar to Amgen's Enbrel

Last Updated: 2016-08-30

By Reuters Staff

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Novartis AG's biosimilar version of Amgen Inc's arthritis drug Enbrel (etanercept).

The FDA approved the drug, Erelzi, known also as etanercept-szzs, for multiple inflammatory conditions including rheumatoid arthritis and plaque psoriasis, a skin condition.

The agency approved the drug as a biosimilar, meaning there is no clinically meaningful differences between Erelzi and Enbrel. However, the two drugs are not considered interchangeable and are therefore not called generics.

The FDA's ruling followed a unanimous vote by the agency's advisory panel in July in favor of approval.

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.